Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical Inc (RMTI) delivers innovative therapies for chronic kidney disease and hemodialysis patients, including the only FDA-approved iron replacement therapy administered via dialysate. This page provides investors and healthcare professionals with centralized access to official press releases, clinical trial updates, and business developments directly impacting renal care innovation.
Track RMTI's progress in advancing dialysis solutions like triferic® and critical concentrates that maintain metabolic balance during treatment. Stay informed about regulatory milestones, partnership announcements, and research breakthroughs that shape the company's role in improving patient outcomes.
Key updates across three focus areas: iron deficiency management advancements, dialysis product innovations, and strategic initiatives enhancing renal care delivery. Bookmark this resource for verified information on RMTI's contributions to reducing treatment complications in ESRD patients.
Rockwell Medical (Nasdaq: RMTI) announced it will release its financial and operational results for the second quarter of 2024 on August 8, 2024. The announcement will be made at 6:00am ET, followed by a live conference call and webcast at 8:00am ET. Rockwell Medical, a healthcare company specializing in hemodialysis products, will discuss the financial and operational results for the quarter ending June 30, 2024, and hold a Q&A session. The conference can be accessed via phone at (888) 660-6347 (domestic) or (929) 201-6594 (international) using Conference Call ID: 4944610, or via webcast at www.RockwellMed.com/Results.
Rockwell Medical (Nasdaq: RMTI) has promoted Tim Chole to the position of Chief Commercial Officer. Chole has been with the company since December 2019, initially serving as SVP of Sales and Marketing. In his new role, he will report to President and CEO Dr. Mark Strobeck. This promotion follows Rockwell's strategic shift in November 2022, aimed at enhancing revenue-generating businesses and driving profitability. Chole has over 20 years of experience in commercial roles within the pharmaceutical and medical device sectors, with a strong focus on renal care. Under his leadership, Rockwell has increased market share, improved gross margins, and achieved record net sales.
Rockwell Medical (Nasdaq: RMTI) reported record net sales of $22.7 million for Q1 2024, a 15% year-over-year increase. Gross profit rose 18% to $3.1 million, and gross margin improved to 14%. The net loss narrowed to $1.7 million, with adjusted EBITDA at ($0.5) million. The company raised its 2024 guidance, expecting net sales of $90-$94 million and gross profit of $13-$15 million. Rockwell Medical signed new distribution agreements and extended a loan maturity date, reducing interest rates. Cash reserves stood at $10.2 million at the end of Q1 2024.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
